Evaluating the Safety and Efficacy of Biosimilars in Rheumatologic Practice

The introduction of biosimilars into rheumatologic practice has transformed the therapeutic landscape for autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. Biosimilars, developed to be highly similar to reference biologics in terms of efficacy, safety, and immunogenicity, offer a promising solution to the increasing demand for cost-effective biologic therapies. Despite regulatory approvals and positive results from clinical trials, skepticism persists among healthcare providers and patients, particularly concerning long-term safety and interchangeability. This review critically examines the current evidence on the clinical performance of biosimilars in rheumatology, focusing on efficacy, safety, immunogenicity, and pharmacovigilance. It also discusses regulatory frameworks, physician attitudes, and patient perceptions that influence the adoption of biosimilars. The findings support that, under rigorous evaluation, biosimilars are reliable alternatives to originator biologics. However, the successful integration of biosimilars requires continued education, real-world data collection, and robust surveillance systems to monitor adverse effects and therapeutic outcomes over time.